HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.
2009, Int J Cancer. 2009 Jun 15. [Epub ahead of print]
Soler M, Mancini F, Meca-Cortés O, Sánchez-Cid L, Rubio N, López-Fernández S, José Lozano J, Blanco J, Fernández PL, Thomson TM.
Autors del centre relacionats: Blanco Jerónimo, Rubio Nuria.
Soler M, Mancini F, Meca-Cortés O, Sánchez-Cid L, Rubio N, López-Fernández S, José Lozano J, Blanco J, Fernández PL, Thomson TM.
Autors del centre relacionats: Blanco Jerónimo, Rubio Nuria.
Department of Molecular and Cell Biology, Barcelona Molecular Biology Institute, CSIC, Barcelona, Spain.
HER3 (ERBB3) is a catalytically inactive pseudokinase of the HER receptor tyrosine kinase family, frequently overexpressed in prostate and other cancers. Aberrant expression and mutations of two other members of the family, EGFR and HER2, are key carcinogenic events in several types of tumors, and both are well-validated therapeutic targets. In this study we show that HER3 is required to maintain the motile and invasive phenotypes of prostate (DU-145) and breast (MCF-7) cancer cells in response to the HER3 ligand neuregulin-1 (NRG-1), epidermal growth factor (EGF) and fetal bovine serum. While MCF-7 breast cancer cells appeared to require HER3 as part of an autocrine response induced by EGF and FBS, the response of DU-145 prostate cancer cells to these stimuli, while requiring HER3, did not appear to involve autocrine stimulation of the receptor. DU-145 cells required the expression of HER3 for efficient clonogenicity in vitro in standard growth medium and for tumorigenicity in immunodeficient mice. These observations suggest that prostate cancer cells derived from tumors that overexpress HER3 are dependent on its expression for the maintenance of major attributes of neoplastic aggressiveness, with or without cognate ligand stimulation. (c) 2009 UICC.
HER3 (ERBB3) is a catalytically inactive pseudokinase of the HER receptor tyrosine kinase family, frequently overexpressed in prostate and other cancers. Aberrant expression and mutations of two other members of the family, EGFR and HER2, are key carcinogenic events in several types of tumors, and both are well-validated therapeutic targets. In this study we show that HER3 is required to maintain the motile and invasive phenotypes of prostate (DU-145) and breast (MCF-7) cancer cells in response to the HER3 ligand neuregulin-1 (NRG-1), epidermal growth factor (EGF) and fetal bovine serum. While MCF-7 breast cancer cells appeared to require HER3 as part of an autocrine response induced by EGF and FBS, the response of DU-145 prostate cancer cells to these stimuli, while requiring HER3, did not appear to involve autocrine stimulation of the receptor. DU-145 cells required the expression of HER3 for efficient clonogenicity in vitro in standard growth medium and for tumorigenicity in immunodeficient mice. These observations suggest that prostate cancer cells derived from tumors that overexpress HER3 are dependent on its expression for the maintenance of major attributes of neoplastic aggressiveness, with or without cognate ligand stimulation. (c) 2009 UICC.
Institut Català de Ciències Cardiovasculars
Hospital de la Santa Creu i Sant Pau, Pavelló del Convent
Sant Antoni Maria Claret, 167 08025 Barcelona
Espanya
T: +34 - 93 556 5900 F: +34 - 93 556 5559